Add-on Acquisition • Life Science

Quantum BioPharma Acquires Lucid Psycheceuticals

On August 25, 2021, Quantum BioPharma acquired life science company Lucid Psycheceuticals for 9M USD

Acquisition Context

This is Quantum BioPharma’s 2nd transaction in the Life Science sector.
This is Quantum BioPharma’s 2nd largest (disclosed) transaction.
This is Quantum BioPharma’s 1st transaction in Canada.
This is Quantum BioPharma’s 1st transaction in Ontario.

Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	August 25, 2021
Target	Lucid Psycheceuticals
Sector	Life Science
Buyer(s)	Quantum BioPharma
Deal Type	Add-on Acquisition
Deal Value	9M USD

Target Company

Lucid Psycheceuticals

Toronto, Ontario, Canada

Lucid Psycheceuticals is a specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases. The company's team is composed of highly specialized science experts focused on providing leading-edge small molecule therapeutics for total brain health. Lucid Psycheceuticals is based in Toronto, Ontario.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Quantum BioPharma

Toronto, Ontario, Canada

Category	Company
Founded	1998
Sector	Life Science
Employees	9

DESCRIPTION

Quantum BioPharma is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Quantum BioPharma was founded in 1998 and is based in Toronto, Ontario.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	2 of 2
State: Ontario	1 of 1
Country: Canada	1 of 1
Year: 2021	1 of 1
Size (of disclosed)	2 of 2

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2019-04-23	Prismic Pharmaceuticals Worcester, Massachusetts, United States Prismic Pharmaceuticals, Inc. is a pharmaceutical company dedicated to addressing the opioid crisis by developing novel non-addictive prescription drugs for the treatment of pain, inflammation, and neurological disorders, based on formulations utilizing the company’s micro-PEA development platform (palmitoylethanolamide with particle sizes of 0.6 – 10 microns). Prismic Pharmaceuticals, Inc. was founded in 2011 and is based in Worcester, Massachusetts.	Buy	$18M

DATE

TARGET

DEAL TYPE

VALUE

2019-04-23

Prismic Pharmaceuticals

Worcester, Massachusetts, United States

Prismic Pharmaceuticals, Inc. is a pharmaceutical company dedicated to addressing the opioid crisis by developing novel non-addictive prescription drugs for the treatment of pain, inflammation, and neurological disorders, based on formulations utilizing the company’s micro-PEA development platform (palmitoylethanolamide with particle sizes of 0.6 – 10 microns). Prismic Pharmaceuticals, Inc. was founded in 2011 and is based in Worcester, Massachusetts.

Buy

$18M

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Ontario M&A - Canada M&A - 2021 M&A